Description: Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
Home Page: www.genenta.com
Via Olgettina No. 58
Milan,
MI
20132
Italy
Phone:
39 02 26 43 46 81
Officers
| Name | Title |
|---|---|
| Mr. Pierluigi Paracchi | Co-Founder, Chairman & CEO |
| Dr. Luigi Naldini M.D., Ph.D. | Co-Founder & Chairman of the Executive Scientific Board |
| Dr. Bernard Rudolph Gentner M.D., Ph.D. | Co-Founder & Member of the Executive Scientific Board |
| Mr. Richard B. Slansky | Chief Financial Officer |
| Dr. Carlo Russo M.D. | Chief Medical Officer & Head of Development |
| Dr. Stefania Mazzoleni Ph.D. | Director of Program Development |
| Ms. Barbara Regonini | Director of Finance |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.0681 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 14 |